Skip Navigation


Carcinogenesis Advance Access originally published online on October 4, 2007
Carcinogenesis 2008 29(1):194-201; doi:10.1093/carcin/bgm219
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
29/1/194    most recent
bgm219v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Raj, D.
Right arrow Articles by Grossman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raj, D.
Right arrow Articles by Grossman, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Survivin repression by p53, Rb and E2F2 in normal human melanocytes

Deepak Raj2, Tong Liu3, George Samadashwily3, Fengzhi Li4 and Douglas Grossman1,2,3,*

1 Department of Dermatology, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA
2 Department of Oncological Sciences
3 Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, USA
4 Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA

* To whom correspondence should be addressed. Tel: +1 801 581 4682; Fax: +1 801 585 0900; Email: doug.grossman{at}hci.utah.edu

The inhibitor of apoptosis protein survivin is a dual mediator of apoptosis resistance and cell cycle progression and is highly expressed in cancer. We have shown previously that survivin is up-regulated in melanoma compared with normal melanocytes, is required for melanoma cell viability, and that melanocyte expression of survivin predisposes mice to ultraviolet-induced melanoma and metastasis. The mechanism of survivin up-regulation in the course of melanocyte transformation and its repression in normal melanocytes, however, has not been clearly defined. We show here that p53 and retinoblastoma (Rb), at basal levels and in the absence of any activating stimuli, are both required to repress survivin transcription in normal human melanocytes. Survivin repression in melanocytes does not involve alterations in protein stability or promoter methylation. p53 and Rb (via E2Fs) regulate survivin expression by direct binding to the survivin promoter; p53 also affects survivin expression by activating p21. We demonstrate a novel role for E2F2 in the negative regulation of survivin expression. In addition, we identify a novel E2F-binding site in the survivin promoter and show that mutation of either the p53- or E2F-binding sites is sufficient to increase promoter activity. These studies suggest that compromise of either p53 or Rb pathways during melanocyte transformation leads to up-regulation of survivin expression in melanoma.

Abbreviations: DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid; HEPES, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; Rb, retinoblastoma; siRNA, small interfering RNA; RNAi, RNA interference

Received July 24, 2007; revised September 17, 2007; accepted September 23, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Conway, A. Mitra, R. Jewell, J. Randerson-Moor, S. Lobo, J. Nsengimana, S. Edward, D. S. Sanders, M. Cook, B. Powell, et al.
Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival
Clin. Cancer Res., November 15, 2009; 15(22): 6939 - 6946.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. Lu, S. C. Verma, M. Murakami, Q. Cai, P. Kumar, B. Xiao, and E. S. Robertson
Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Upregulates Survivin Expression in KSHV-Associated B-Lymphoma Cells and Contributes to Their Proliferation
J. Virol., July 15, 2009; 83(14): 7129 - 7141.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic
Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas
Cancer Res., May 1, 2008; 68(9): 3124 - 3132.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.